Mr. Sebastien Plouffe reports

DEFENCE THERAPEUTICS RECEIVES USPTO ALLOWANCE FOR PATENT APPLICATION COVERING NEXT-GEN ADC TECHNOLOGY

The U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance for its U.S. patent application covering one of its next-generation antibody-drug conjugate (ADC) technologies. The allowance of U.S. patent application No. 18/351,291 includes valuable composition-of-matter claims broadly covering therapeutically active ADCs -- not limited to individual diseases or therapeutic targets -- as well as claims covering the use of ADCs for treating or diagnosing diseases such as cancer.

Defence's Accum-based ADCs have demonstrated enhanced intracellular delivery and cytotoxic activity in multiple preclinical cancer models compared with conventional ADCs. Upon grant, the 291 patent application will provide the company with potential market exclusivity until 2043 for its proprietary second-generation Accum-based ADCs, which include antibodies conjugated to innovative new constructs featuring a bile acid conjugated to a nuclear localization signal (NLS) derived from the ribosomal protein eS17 (RPS17).

This milestone builds on Defence's established patent portfolio for its foundational Accum technology, which includes granted patents in the United States (U.S. No. 11,352,437), Japan (JP No. 7,126,956), Australia (AU No. 2017233725) and Israel (IL No. 261765), with applications currently pending in Canada and Europe.

"Second-generation Accum-based ADCs represent a significant advancement in both oncotherapy and targeted drug delivery," said Sebastien Plouffe, chief executive officer and founder of Defence Therapeutics. "This recent allowance underscores the innovation and versatility embedded in our ADC platform technology and reflects our commitment to developing novel, effective cancer treatments that push the boundaries of current ADC technologies."

This newly allowed U.S. patent application is poised to become the eighth granted U.S. patent in Defence's expanding portfolio, which now comprises seven published patent families.

About Defence Therapeutics Inc.

Defence Therapeutics is a publicly traded clinical-stage biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics' platform is the Accum technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.

We seek Safe Harbor.